The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies
Christopher K Taylor,
Robert M Levy,
Jay C Elliott,
Bruce P Burnett,
Christopher K Taylor
Primus Pharmaceuticals, Inc., Scottsdale, Arizona, USA
Search for more papers by this authorRobert M Levy
Primus Pharmaceuticals, Inc., Scottsdale, Arizona, USA
Search for more papers by this authorJay C Elliott
Primus Pharmaceuticals, Inc., Scottsdale, Arizona, USA
Search for more papers by this authorCorresponding Author
Bruce P Burnett
Primus Pharmaceuticals, Inc., Scottsdale, Arizona, USA
BP Burnett, Primus Pharmaceuticals, Inc., 4725 N. Scottsdale Rd. Ste. #200, Scottsdale, AZ 85201, USA. E-mail: [email protected], Phone: +1-480-483-1410, Fax: +1-480-483-2604.Search for more papers by this authorChristopher K Taylor,
Robert M Levy,
Jay C Elliott,
Bruce P Burnett,
Christopher K Taylor
Primus Pharmaceuticals, Inc., Scottsdale, Arizona, USA
Search for more papers by this authorRobert M Levy
Primus Pharmaceuticals, Inc., Scottsdale, Arizona, USA
Search for more papers by this authorJay C Elliott
Primus Pharmaceuticals, Inc., Scottsdale, Arizona, USA
Search for more papers by this authorCorresponding Author
Bruce P Burnett
Primus Pharmaceuticals, Inc., Scottsdale, Arizona, USA
BP Burnett, Primus Pharmaceuticals, Inc., 4725 N. Scottsdale Rd. Ste. #200, Scottsdale, AZ 85201, USA. E-mail: [email protected], Phone: +1-480-483-1410, Fax: +1-480-483-2604.Search for more papers by this authorAbstract
In Asian epidemiological studies, health benefits, including reduced incidence of breast and prostate cancers, are attributed to soy food and isoflavone consumption. The recent increased intake of soy foods and supplements in the American diet has raised concerns about the possible estrogen-like effects of natural isoflavones and possible promotion or propagation of estrogen-sensitive cancers. These concerns are primarily based on in vitro and rodent data which suggest that genistein aglycone can stimulate tumor cell proliferation and growth in mice having deficient immune systems. In contrast, a recent nested case-control study and meta-analysis of numerous epidemiological studies show an inverse correlation between genistein intake and breast cancer risk. Furthermore, clinical studies in osteopenic and osteoporotic, postmenopausal women support the breast and uterine safety of purified naturally derived genistein administered for up to 3 years. In this review, we summarize the in vitro, preclinical and clinical evidence for the safety of natural genistein.
REFERENCES
- 1 Magee PJ, Rowland IR. Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr. 2004; 91: 513–531.
- 2 Munro IC, Harwood M, Hlywka JJ, Stephen AM, Doull J, Flamm WG, et al. Soy isoflavones: a safety review. Nutr Rev. 2003; 61: 1–33.
- 3 Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst. 2006; 98: 459–471.
- 4 Messina M, Ho S, Alekel DL. Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data. Curr Opin Clin Nutr Metab Care. 2004; 7: 649–658.
- 5 Messina M, Nagata C, Wu AH. Estimated Asian adult soy protein and isoflavone intakes. Nutr Cancer. 2006; 55: 1–12.
- 6 Seo HS, DeNardo DG, Jacquot Y, Laios I, Vidal DS, Zambrana CR, et al. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res Treat. 2006; 99: 121–134.
- 7 Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res. 2001; 61: 5045–5050.
- 8 Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N, et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res. 2002; 17: 1904–1912.
- 9 Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann Intern Med. 2007; 146: 839–847.
- 10 Marini H, Minutoli L, Polito F, Bitto A, Altavilla D, Atteritano M, et al. OPG and sRANKL serum concentrations in osteopenic, postmenopausal women after 2-year genistein administration. J Bone Miner Res. 2008; 23: 715–720.
- 11 D'Anna R, Cannata ML, Atteritano M, Cancellieri F, Corrado F, Baviera G, et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 1-year randomized, double-blind, placebo-controlled study. Menopause. 2007; 14: 648–655.
- 12 Crisafulli A, Marini H, Bitto A, Altavilla D, Squadrito G, Romeo A, et al. Effects of genistein on hot flushes in early postmenopausal women: a randomized, double-blind EPT- and placebo-controlled study. Menopause. 2004; 11: 400–404.
- 13 Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, et al. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev. 2006; 58: 773–781.
- 14 Deroo BJ, Kenneth S, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006; 116: 561–570.
- 15 Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 1986; 320: 134–139.
- 16 Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science. 1986; 231: 1150–1154.
- 17 Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996; 392: 49–53.
- 18 Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 1996; 93: 5925–5930.
- 19 Li X, Huang J, Yi P, Bambara RA, Hilf R, Muyan M. Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways. Mol Cell Biol. 2004; 24: 7681–7694.
- 20 Arts J, Kuiper GG, Janssen JM, Gustafsson JA, Lowik CW, Pols HA, et al. Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology. 1997; 138: 5067–5070.
- 21 Yaghmaie F, Saeed O, Garan SA, Freitag W, Timiras PS, Sternberg H. Caloric restriction reduces cell loss and maintains estrogen receptor-alpha immunoreactivity in the pre-optic hypothalamus of female B6D2F1 mice. Neuro Endocrinol Lett. 2005; 26: 197–203.
- 22 Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology. 1997; 138: 4613–4621.
- 23 Babiker FA, De Windt LJ, Van Eickels M, Grohe C, Meyer R, Doevendans PA. Estrogenic hormone action in the heart: regulatory network and function. Cardiovasc Res. 2002; 53: 709–719.
- 24 Beekman JM, Allan GF, Tsai SY, Tsai MJ, O'Malley BW. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Mol Endocrinol. 1993; 7: 1266–1274.
- 25 Tsai MJ, O'Malley BW. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem. 1994; 63: 451–486.
- 26 Beato M, Sanchez-Pacheco A. Interaction of steroid hormone receptors with the transcription initiation complex. Endocr Rev. 1996; 17: 587–609.
- 27 Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006; 116: 561–570.
- 28 Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997; 138: 863–870.
- 29 Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, Van Der Saag PT, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 1998; 139: 4252–4263.
- 30 Hsieh RW, Rajan SS, Sharma SK, Guo Y, DeSombre ER, Mrksich M, et al. Identification of ligands with bicyclic scaffolds provides insights into mechanisms of estrogen receptor subtype selectivity. J Biol Chem. 2006; 281: 17909–17919.
- 31 Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol. 1998; 54: 105–112.
- 32 Teede HJ, Dalais FS, Kotsopoulos D, McGrath BP, Malan E, Gan TE, et al. Dietary soy containing phytoestrogens does not activate the hemostatic system in postmenopausal women. J Clin Endocrinol Metab. 2005; 90: 1936–1941.
- 33 Yildiz MF, Kumru S, Godekmerdan A, Kutlu S. Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women. Int J Gynaecol Obstet. 2005; 90: 128–133.
- 34 D'Anna R, Baviera G, Corrado F, Cancellieri F, Crisafulli A, Squadrito F. The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women. Acta Obstet Gynecol Scand. 2005; 84: 474–477.
- 35 Crisafulli A, Altavilla D, Marini H, Bitto A, Cucinotta D, Frisina N, et al. Effects of the phytoestrogen genistein on cardiovascular risk factors in postmenopausal women. Menopause. 2005; 12: 186–192.
- 36 Marini H, Bitto A, Altavilla D, Burnett B, Polito F, Minutoli L, et al. Breast safety and efficacy of genistein aglycone for post-menopausal bone loss: a follow-up study. J Clin Endocrinol Metab. 2008; 93: 4787–4796.
- 37 Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J. 1999; 18: 4608–4618.
- 38 Kostelac D, Rechkemmer G, Briviba K. Phytoestrogens modulate binding response of estrogen receptors alpha and beta to the estrogen response element. J Agric Food Chem. 2003; 51: 7632–7635.
- 39 Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 2004; 64: 423–428.
- 40 Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA. 2004; 101: 1566–1571.
- 41 Chang EC, Frasor J, Komm B, Katzenellenbogen BS. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology. 2006; 147: 4831–4842.
- 42 Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997; 389: 753–758.
- 43 Manas ES, Xu ZB, Unwalla RJ, Somers WS. Understanding the selectivity of genistein for human estrogen receptor-beta using X-ray crystallography and computational methods. Structure. 2004; 12: 2197–2207.
- 44 Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996; 11: 835–842.
- 45 Gustafsson JA. Estrogen receptor beta – a new dimension in estrogen mechanism of action. J Endocrinol. 1999; 163: 379–383.
- 46 Jordan VC. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. J Natl Cancer Inst. 1998; 90: 967–971.
- 47 An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, Leitman DC. Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem. 2001; 276: 17808–17814.
- 48 Yue W, Wang JP, Li Y, et al. Tamoxifen versus aromatase inhibitors for breast cancer prevention. Clin Cancer Res. 2005; 11(Suppl): S925–S930.
- 49 Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch. 2004; 444: 213–223.
- 50 Chu S, Mamers P, Burger HG, Fuller PJ. Estrogen receptor isoform gene expression in ovarian stromal and epithelial tumors. J Clin Endocrinol Metab. 2000; 85: 1200–1205.
- 51 Tsutsui T, Tamura Y, Yagi E, Someya H, Hori I, Metzler M, et al. Cell-transforming activity and mutagenicity of 5 phytoestrogens in cultured mammalian cells. Int J Cancer. 2003; 105: 312–320.
- 52 Setchell KD, Brown NM, Desai P, Zimmer-Nechemias L, Wolfe BE, Brashear WT, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr. 2001; 131(Suppl): S1362–S1375.
- 53 Ullmann U, Oberwittle H, Grossmann M, Riegger C. Repeated oral once daily intake of increasing doses of the novel synthetic genistein product Bonistein in healthy volunteers. Planta Med. 2005; 71: 891–896.
- 54 McClain RM, Wolz E, Davidovich A, Pfannkuch F, Bausch J. Subchronic and chronic safety studies with genistein in dogs. Food Chem Toxicol. 2005; 43: 1461–1482.
- 55 Di Virgilio AL, Iwami K, Watjen W, Kahl R, Degen GH. Genotoxicity of the isoflavones genistein, daidzein and equol in V79 cells. Toxicol Lett. 2004; 151: 151–162.
- 56 Michael McClain R, Wolz E, Davidovich A, Pfannkuch F, Edwards JA, Bausch J. Acute, subchronic and chronic safety studies with genistein in rats. Food Chem Toxicol. 2006; 44: 56–80.
- 57 Rozman KK, Bhatia J, Calafat AM, Chambers C, Culty M, Etzel RA, et al. NTP-CERHR expert panel report on the reproductive and developmental toxicity of genistein. Birth Defects Res B Dev Reprod Toxicol. 2006; 77: 485–638.
- 58 Giri AK, Lu LJ. Genetic damage and the inhibition of 7,12-dimethylbenz[a]anthracene-induced genetic damage by the phytoestrogens, genistein and daidzein, in female ICR mice. Cancer Lett. 1995; 95: 125–133.
- 59 Delclos KB, Newbold R. NTP toxicity report of reproductive dose range-finding study of genistein (CAS No. 446-72-0) administered in feed to sprague-dawley rats. Toxic Rep Ser. 2007; 79: 1–98.
- 60 National Toxicology Program. NTP toxicology and carcinogenesis studies of genistein (CAS No. 446-72-0) in Sprague-Dawley rats (feed study). Research Triangle Park, NC; 2008 Jan. Report No.: 0888-8051 (Print).
- 61 National Toxicology Program. NTP multigenerational reproductive study of genistein (CAS No. 446-72-0) in Sprague-Dawley rats (feed study). Research Triangle Park, NC; 2008 Mar. Report No.: 0888-8051 (Print).
- 62 Rucinska A, Roszczyk M, Gabryelak T. Cytotoxicity of the isoflavone genistein in NIH 3T3 cells. Cell Biol Int. 2008; 32: 1019–1023.
- 63 Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst. 1973; 51: 1409–1416.
- 64 Fioravanti L, Cappelletti V, Miodini P, Ronchi E, Brivio M, Di Fronzo G. Genistein in the control of breast cancer cell growth: insights into the mechanism of action in vitro. Cancer Lett. 1998; 130: 143–152.
- 65 Le Bail JC, Varnat F, Nicolas JC, Habrioux G. Estrogenic and antiproliferative activities on MCF-7 human breast cancer cells by flavonoids. Cancer Lett. 1998; 130: 209–216.
- 66 Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res. 1998; 58: 3833–3838.
- 67 Jeune MA, Kumi-Diaka J, Brown J. Anticancer activities of pomegranate extracts and genistein in human breast cancer cells. J Med Food. 2005; 8: 469–475.
- 68 Liu Y, Zhang YM, Song DF, Cui HB. Effect of apoptosis in human breast cancer cells and its probable mechanisms by genistein. Wei Sheng Yan Jiu. 2005; 34: 67–69.
- 69 Farina HG, Pomies M, Alonso DF, Gomez DE. Antitumor and antiangiogenic activity of soy isoflavone genistein in mouse models of melanoma and breast cancer. Oncol Rep. 2006; 16: 885–891.
- 70 Mai Z, Blackburn GL, Zhou JR. Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice. Carcinogenesis. 2007; 28: 1217–1223.
- 71 Valachovicova T, Slivova V, Bergman H, Shuherk J, Sliva D. Soy isoflavones suppress invasiveness of breast cancer cells by the inhibition of NF-kappaB/AP-1-dependent and -independent pathways. Int J Oncol. 2004; 25: 1389–1395.
- 72 Mai Z, Blackburn GL, Zhou JR. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells. Mol Carcinog. 2007; 46: 534–542.
- 73 Satoh H, Nishikawa K, Suzuki K, Asano R, Virgona N, Ichikawa T, et al. Genistein, a soy isoflavone, enhances necrotic-like cell death in a breast cancer cell treated with a chemotherapeutic agent. Res Commun Mol Pathol Pharmacol. 2003; 113–114: 149–158.
- 74 Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005; 65: 6934–6942.
- 75 Mohammad RM, Banerjee S, Li Y, Aboukameel A, Kucuk O, Sarkar FH. Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer. 2006; 106: 1260–1268.
- 76 Li Y, Ellis KL, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O, et al. Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas. 2004; 28: e90–95.
- 77 Gong L, Li Y, Nedeljkovic-Kurepa A, Sarkar FH. Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene. 2003; 22: 4702–4709.
- 78 Kousidou OC, Mitropoulou TN, Roussidis AE, Kletsas D, Theocharis AD, Karamanos NK. Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. Int J Oncol. 2005; 26: 1101–1109.
- 79 Regenbrecht CR, Jung M, Lehrach H, Adjaye J. The molecular basis of phytoestrogen genistein induced mitotic arrest and exit of self-renewal in embryonal carcinoma and primary cancer cell lines. BMC Med Genomics. 2008; 1: 49.
- 80 Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987; 262: 5592–5595.
- 81 Okura A, Arakawa H, Oka H, Yoshinari T, Monden Y. Effect of genistein on topoisomerase activity and on the growth of [Val 12]Ha-ras-transformed NIH 3T3 cells. Biochem Biophys Res Commun. 1988; 157: 183–189.
- 82 Cho KH, Pezzuto JM, Bolton JL, Steele VE, Kelloff GJ, Lee SK, et al. Selection of cancer chemopreventive agents based on inhibition of topoisomerase II activity. Eur J Cancer. 2000; 36: 2146–2156.
- 83 Choi YH, Lee WH, Park KY, Zhang L. p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Japan J Cancer Res. 2000; 91: 164–173.
- 84 Wei H, Wei L, Frenkel K, Bowen R, Barnes S. Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr Cancer. 1993; 20: 1–12.
- 85 Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein. Cancer Lett. 2008; 269: 226–242.
- 86 Fan S, Meng Q, Auborn K, Carter T, Rosen EM. BRCA1 and BRCA2 as molecular targets for phytochemicals indole-3-carbinol and genistein in breast and prostate cancer cells. Br J Cancer. 2006; 94: 407–426.
- 87 Caetano B, Le Corre L, Chalabi N, Delort L, Bignon YJ, Bernard-Gallon DJ. Soya phytonutrients act on a panel of genes implicated with BRCA1 and BRCA2 oncosuppressors in human breast cell lines. Br J Nutr. 2006; 95: 406–413.
- 88 Thasni KA, Rojini G, Rakesh SN, Ratheeshkumar T, Babu MS, Srinivas G, et al. Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on breast cancer susceptibility gene-1 (BRCA1) status. Eur J Pharmacol. 2008; 588: 158–164.
- 89 Liu B, Edgerton S, Yang X, Kim A, Ordonez-Ercan D, Mason T, et al. Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res. 2005; 65: 879–886.
- 90 Kinjo J, Tsuchihashi R, Morito K, Hirose T, Aomori T, Nagao T, et al. Interactions of phytoestrogens with estrogen receptors alpha and beta (III). Estrogenic activities of soy isoflavone aglycones and their metabolites isolated from human urine. Biol Pharm Bull. 2004; 27: 185–188.
- 91 Schwartz JA, Liu G, Brooks SC. Genistein-mediated attenuation of tamoxifen-induced antagonism from estrogen receptor-regulated genes. Biochem Biophys Res Commun. 1998; 253: 38–43.
- 92 Limer JL, Parkes AT, Speirs V. Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro. Int J Cancer. 2006; 119: 515–521.
- 93 Santell RC, Kieu N, Helferich WG. Genistein inhibits growth of estrogen-independent human breast cancer cells in culture but not in athymic mice. J Nutr. 2000; 130: 1665–1669.
- 94 Allred CD, Allred KF, Ju YH, Clausen LM, Doerge DR, Schantz SL, et al. Dietary genistein results in larger MNU-induced, estrogen-dependent mammary tumors following ovariectomy of Sprague-Dawley rats. Carcinogenesis. 2004; 25: 211–218.
- 95 Ju YH, Allred CD, Allred KF, Karko KL, Doerge DR, Helferich WG. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr. 2001; 131: 2957–2962.
- 96 Messina M, McCaskill-Stevens W, Lampe JW. Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings. J Natl Cancer Inst. 2006; 98: 1275–1284.
- 97 Upadhyaya P, El-Bayoumy K. Effect of dietary soy protein isolate, genistein, and 1,4-phenylenebis(methylene)selenocyanate on DNA binding of 7,12-dimethylbenz[a]anthracene in mammary glands of CD rats. Oncol Rep. 1998; 5: 1541–1545.
- 98 Lamartiniere CA, Moore JB, Brown NM, Thompson R, Hardin MJ, Barnes S. Genistein suppresses mammary cancer in rats. Carcinogenesis. 1995; 16: 2833–2840.
- 99 Lamartiniere CA. Timing of exposure and mammary cancer risk. J Mammary Gland Biol Neoplasia. 2002; 7: 67–76.
- 100 Constantinou AI, Lantvit D, Hawthorne M, Xu X, Van Breemen RB, Pezzuto JM. Chemopreventive effects of soy protein and purified soy isoflavones on DMBA-induced mammary tumors in female Sprague-Dawley rats. Nutr Cancer. 2001; 41: 75–81.
- 101 Lamartiniere CA. Protection against breast cancer with genistein: a component of soy. Am J Clin Nutr. 2000; 71(Suppl): S1705–S1707; discussion S1708–S1709.
- 102 Harris RM, Wood DM, Bottomley L, Blagg S, Owen K, Hughes PJ, et al. Phytoestrogens are potent inhibitors of estrogen sulfation: implications for breast cancer risk and treatment. J Clin Endocrinol Metab. 2004; 89: 1779–1787.
- 103 Levenson AS, Jordan VC. MCF-7: the first hormone-responsive breast cancer cell line. Cancer Res. 1997; 57: 3071–3078.
- 104 Vantyghem SA, Wilson SM, Postenka CO, Al-Katib W, Tuck AB, Chambers AF. Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model. Cancer Res. 2005; 65: 3396–3403.
- 105 Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD. MDA-MB-435 cells are derived from M14 melanoma cells – a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat. 2007; 104: 13–19.
- 106 Wood CE, Register TC, Anthony MS, Kock ND, Cline JM. Breast and uterine effects of soy isoflavones and conjugated equine estrogens in postmenopausal female monkeys. J Clin Endocrinol Metab. 2004; 89: 3462–3468.
- 107 Wood CE, Kaplan JR, Stute P, Cline JM. Effects of soy on the mammary glands of premenopausal female monkeys. Fertil Steril. 2006; 85(Suppl): 1179–1186.
- 108 Wood CE, Register TC, Franke AA, Anthony MS, Cline JM. Dietary soy isoflavones inhibit estrogen effects in the postmenopausal breast. Cancer Res. 2006; 66: 1241–1249.
- 109 Wood CE, Appt SE, Clarkson TB, Franke AA, Lees CJ, Doerge DR, et al. Effects of high-dose soy isoflavones and equol on reproductive tissues in female cynomolgus monkeys. Biol Reprod. 2006; 75: 477–486.
- 110 Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 2002; 62: 2474–2477.
- 111 Ju YH, Allred KF, Allred CD, Helferich WG. Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis. 2006; 27: 1292–1299.
- 112 Razandi M, Pedram A, Rosen EM, Levin ER. BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol Cell Biol. 2004; 24: 5900–5913.
- 113 Boulton SJ. Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans. 2006; 34: 633–645.
- 114 Atteritano M, Pernice F, Mazzaferro S, Mantuano S, Frisina A, D'Anna R, et al. Effects of phytoestrogen genistein on cytogenetic biomarkers in postmenopausal women: 1 year randomized, placebo-controlled study. Eur J Pharmacol. 2008; 589: 22–26.
- 115 Maskarinec G, Takata Y, Franke AA, Williams AE, Murphy SP. A 2-year soy intervention in premenopausal women does not change mammographic densities. J Nutr. 2004; 134: 3089–3094.
- 116 Maskarinec G, Williams AE, Carlin L. Mammographic densities in a one-year isoflavone intervention. Eur J Cancer Prev. 2003; 12: 165–169.
- 117 Maskarinec G, Williams AE, Inouye JS, Stanczyk FZ, Franke AA. A randomized isoflavone intervention among premenopausal women. Cancer Epidemiol Biomarkers Prev. 2002; 11: 195–201.
- 118 Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993; 15: 17–35.
- 119 Lu LJ, Cree M, Josyula S, Nagamani M, Grady JJ, Anderson KE. Increased urinary excretion of 2-hydroxyestrone but not 16alpha-hydroxyestrone in premenopausal women during a soya diet containing isoflavones. Cancer Res. 2000; 60: 1299–1305.
- 120 Lu LJ, Anderson KE, Grady JJ, Kohen F, Nagamani M. Decreased ovarian hormones during a soya diet: implications for breast cancer prevention. Cancer Res. 2000; 60: 4112–4121.
- 121 Lu LJ, Anderson KE, Grady JJ, Nagamani M. Effects of an isoflavone-free soy diet on ovarian hormones in premenopausal women. J Clin Endocrinol Metab. 2001; 86: 3045–3052.
- 122 Hargreaves DF, Potten CS, Harding C, Shaw LE, Morton MS, Roberts SA, et al. Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab. 1999; 84: 4017–4024.
- 123 Brown AM, Jeltsch JM, Roberts M, Chambon P. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci USA. 1984; 81: 6344–6348.
- 124 Rajah TT, Dunn ST, Pento JT. The influence of antiestrogens on pS2 and cathepsin D mRNA induction in MCF-7 breast cancer cells. Anticancer Res. 1996; 16: 837–842.
- 125 Francone OL, Gurakar A, Fielding C. Distribution and functions of lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. Evidence for a functional unit containing these activities together with apolipoproteins A-I and D that catalyzes the esterification and transfer of cell-derived cholesterol. J Biol Chem. 1989; 264: 7066–7072.
- 126 Pearlman WH, Gueriguian JL, Sawyer ME. A specific progesterone-binding component of human breast cyst fluid. J Biol Chem. 1973; 248: 5736–5741.
- 127 McMichael-Phillips DF, Harding C, Morton M, Roberts SA, Howell A, Potten CS, et al. Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am J Clin Nutr. 1998; 68(Suppl): S1431–S1435.
- 128 Duffy C, Cyr M. Phytoestrogens: potential benefits and implications for breast cancer survivors. J Womens Health (Larchmt). 2003; 12: 617–631.
- 129 Sartippour MR, Rao JY, Apple S, Wu D, Henning S, Wang H, et al. A pilot clinical study of short-term isoflavone supplements in breast cancer patients. Nutr Cancer. 2004; 49: 59–65.
- 130 Michael McClain R, Wolz E, Davidovich A, Bausch J. Genetic toxicity studies with genistein. Food Chem Toxicol. 2006; 44: 42–55.
- 131 Nikander E, Kilkkinen A, Metsa-Heikkila M, Adlercreutz H, Pietinen P, Tiitinen A, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol. 2003; 101: 1213–1220.
- 132 Van Patten CL, Olivotto IA, Chambers GK, Gelmon KA, Hislop TG, Templeton E, et al. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol. 2002; 20: 1449–1455.
- 133 Bartholomew RM, Ryan DS. Lack of mutagenicity of some phytoestrogens in the salmonella/mammalian microsome assay. Mutat Res. 1980; 78: 317–321.
- 134 Tham DM, Gardner CD, Haskell WL. Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab. 1998; 83: 2223–2235.
- 135 Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, West DW, et al. Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst. 1993; 85: 1819–1827.
- 136 Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA, Correa P. Geographic pathology of latent prostatic carcinoma. Int J Cancer. 1982; 29: 611–616.
- 137 Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 1989; 49: 1857–1860.
- 138 Iwasaki M, Inoue M, Otani T, Sasazuki S, Kurahashi N, Miura T, et al. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J Clin Oncol. 2008; 26: 1677–1683.
- 139 Verheus M, Van Gils CH, Keinan-Boker L, Grace PB, Bingham SA, Peeters PH. Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol. 2007; 25: 648–655.
- 140 Nagel G, Mack U, Von Fournier D, Linseisen J. Dietary phytoestrogen intake and mammographic density – results of a pilot study. Eur J Med Res. 2005; 10: 389–394.
- 141 Jakes RW, Duffy SW, Ng FC, Gao F, Ng EH, Seow A, et al. Mammographic parenchymal patterns and self-reported soy intake in Singapore Chinese women. Cancer Epidemiol Biomarkers Prev. 2002; 11: 608–613.
- 142 Ursin G, Sun CL, Koh WP, Khoo KS, Gao F, Wu AH, et al. Associations between soy, diet, reproductive factors, and mammographic density in Singapore Chinese women. Nutr Cancer. 2006; 56: 128–135.
- 143 Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998; 7: 1133–1144.
- 144 Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002; 132: 3577–3584.
- 145 Setchell KDR, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am J Clin Nutr. 2003; 78(Suppl): S593–S609.
- 146 Ward H, Chapelais G, Kuhnle GGC, Luben R, Khaw KT, Bingham S. Breast cancer risk in relation to urinary and serum biomarkers of phytoestrogen exposure in the European Prospective into Cancer-Norfolk cohort study. Breast Cancer Res. 2008; 10: R32.
